Pricing Log in Create free account
Friday 6 November 2026 Export ONC’s income statement to Excel — free account

BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

407.83 20.58 +5.31%
Market cap
$40.4B
P/E
65.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BeOne Medicines Ltd. - Sponsored ADR (ONC) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 5 added · 3 removed · 28 modified
P2I1A: no comparison — low extraction confidence
8-K Nov 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 26, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 29 added · 21 removed · 13 modified
P2I1A: no comparison — low extraction confidence
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 26, 2026 8.01 Other events
8-K Jun 11, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
8-K May 13, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 14, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 98 added · 58 removed · 170 modified
1A: 40 added · 17 removed · 96 modified
7: 27 added · 27 removed · 21 modified
8-K Feb 26, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 16, 2025 1.02 Termination of a material definitive agreement
8-K Dec 17, 2025 5.02 Departure or appointment of directors or officers
8-K Nov 13, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation
10-Q Sep 30, 2025
8-K Nov 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 27, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 12, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 7, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 8, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 26, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 26, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 9, 2023 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.